VEU.AX - Vanguard All-World ex-US Shares Index ETF

ASX - ASX Delayed price. Currency in AUD
70.19
+0.14 (+0.20%)
At close: 3:55PM AEDT
Stock chart is not supported by your current browser
Previous close70.05
Open70.04
Bid70.18 x 0
Ask70.25 x 0
Day's range69.92 - 70.27
52-week range69.49 - 73.82
Volume8,717
Avg. volume68,395
Net assets1.26B
NAVN/A
PE ratio (TTM)N/A
Yield3.03%
YTD returnN/A
Beta (3Y monthly)0.82
Expense ratio (net)0.00%
Inception date2009-05-08
  • How you can FIRE on $50,000 per year with this $500,000 ETF portfolio
    Motley Fool3 days ago

    How you can FIRE on $50,000 per year with this $500,000 ETF portfolio

    How this 3 ETF strategy can help you build a $500,000 portfolio and retire early on a passive income of $50,000 per year.

  • US-China Talks and Brexit: Two Big ‘Ifs’ for Markets
    Market Realist6 days ago

    US-China Talks and Brexit: Two Big ‘Ifs’ for Markets

    More Action: US-China Trade Talks Resume Next Week(Continued from Prior Part)US-China talks In the previous part, we discussed that the US (QQQ) and China plan to resume the trade talks next week. So far, China’s economic data have disappointed

  • Can Central Banks Fend Off the Next Recession?
    Market Realist8 days ago

    Can Central Banks Fend Off the Next Recession?

    Economic Slowdown Deepens, Central Banks Take Charge(Continued from Prior Part)Central banks As we discussed previously, central banks in developed economies like the US (SPY), Europe (VGK) (VEU), and Japan (EWJ) have adopted a dovish approach. While

  • What US Investors Need to Know about Emerging Market Risks
    Market Realist6 months ago

    What US Investors Need to Know about Emerging Market Risks

    Among the emerging market (VEU) currencies, the Argentinian peso, Turkish (TUR) lira, Indonesia rupiah, and Indian rupee are declining to all-time lows. The US dollar is also strengthening against all major currencies, including those of emerging markets. As the US dollar strengthens and interest rates rise, the cost of servicing US debt for other countries goes up.

  • How GSK’s Consumer Healthcare Segment Fared in Q1 2018
    Market Realist10 months ago

    How GSK’s Consumer Healthcare Segment Fared in Q1 2018

    GlaxoSmithKline’s (GSK) Consumer Healthcare segment includes various products for oral health, wellness, nutrition, and skin health. The Consumer Healthcare segment reported a 3% fall in its YoY (year-over-year) revenue to ~2.0 billion pounds in Q1 2018 compared to Q1 2017.